Redacted Drug Pricing Records Have Been Released
Public Citizen disclosed terms of pharmaceutical agreements with the U.S. government following a FOIA request.
Updated on Sept. 21, 2026 in Healthcare
Live Poll
Do you trust that government-negotiated pharmaceutical pricing deals will actually lower costs for U.S. patients?
Public Citizen has released redacted documents exposing drug pricing agreements between the U.S. government and 27 pharmaceutical companies. The group warns that these deals, which include tariff exemptions for manufacturers, could negatively impact international drug prices and domestic Medicaid savings.
Why it matters
The government seeks to lower costs for U.S. patients by securing manufacturing pledges and price commitments from drugmakers. Critics argue these agreements may unintentionally allow companies to inflate foreign prices or erode critical Medicaid savings.
The U.S. government has established most favored nation agreements with 27 companies to address pricing discrepancies. An exemption within the Eli Lilly agreement is estimated to cost Medicaid approximately $1.7 billion in potential savings.
The players
Public Citizen
Public Citizen is a non-profit consumer advocacy organization that frequently utilizes litigation and FOIA requests to promote government transparency.
Pfizer
Pfizer is a global pharmaceutical company based in New York that produces a wide range of vaccines and specialty medications.
Eli Lilly
Eli Lilly is a major pharmaceutical manufacturer known for its development of diabetes treatments and weight-loss medications.
Department of Health and Human Services
The Department of Health and Human Services is the U.S. federal agency tasked with protecting the health of all Americans and providing essential human services.
The details
The disclosed documents indicate that Pfizer agreed to allow the Department of Health and Human Services to claim a portion of revenue if the company raises drug prices overseas. While the deals aim to boost domestic R&D and manufacturing, Public Citizen notes that these pharmaceutical companies also secured exemptions from U.S. drug import tariffs.
Timeline
September 2025: Pfizer reached a voluntary agreement with the administration.
January 2026: Public Citizen filed a FOIA lawsuit against HHS.
February 2026: Pfizer entered a definitive MFN deal.
March 2026: Democratic lawmakers requested clarity on Medicaid savings.
September 19, 2026: Public Citizen released findings from the FOIA request.
Market Landscape
These agreements signal a shift in how the government leverages trade policy to regulate pharmaceutical pricing, effectively trading tariff exemptions for cost-containment pledges. This move positions the U.S. against international peers by attempting to force companies to align domestic pricing with global standards.
These agreements aim to lower out-of-pocket drug costs for American patients by curbing price hikes. However, the potential loss of billions in Medicaid savings could impact the long-term financial viability of state and federal health programs.
The takeaway
Transparency regarding federal agreements is essential for understanding how corporate deals impact public health spending. Citizens should monitor whether these manufacturing pledges successfully lower domestic costs without causing unintended increases in drug prices abroad.
Further reading
Learn more about federal efforts to regulate Healthcare costs.
Live Poll
Do you trust that government-negotiated pharmaceutical pricing deals will actually lower costs for U.S. patients?
